262 Users are discussing this topic

PatientPlus articles are written by UK doctors and are based on research evidence, UK and European Guidelines. They are designed for health professionals to use, so you may find the language more technical than the condition leaflets.

See also: Sarcoidosis written for patients

This multisystem chronic inflammatory condition is characterised by the formation of non-caseating epithelioid granulomata at various sites in the body. It has a predilection for the lungs and thoracic cavity, but there are many different manifestations that may cause a great deal of diagnostic difficulty.

Sarcoidosis largely affects patients in their mid-20s to mid-40s but cases do appear infrequently in younger and older patients. After the thorax, the skin and eyes are most commonly affected, followed by the liver (not usually clinically relevant), heart and nervous system.

  • Sarcoidosis occurs worldwide, with a prevalence of about 4·7-64 in 100,000, and an incidence of 1·0-35·5 in 100,000 per year.[1] 
  • The highest rates are reported in northern European/Scandinavian and African–American individuals, and lowest rates are reported in Japan.[1] 
  • Although sarcoidosis may occur at any age, it is usually seen in adults under the age of 50.[2] 
  • In the USA, the lifetime risk of sarcoidosis in the black population is 2.4% and in the white population 0.85%.[3]
  • Sarcoidosis is usually sporadic, but is familial in 3·6-9·6% of cases.[1] 

NEW - log your activity

  • Notes
    Add notes to any clinical page and create a reflective diary
  • Track
    Automatically track and log every page you have viewed
  • Print
    Print and export a summary to use in your appraisal
Click to find out more »

This is highly variable depending on ethnicity, duration of illness, pattern and degree of inflammatory organ involvement.

  • Up to 50% of sufferers in some series were asymptomatic and diagnosed on the basis of routine CXR.
  • There may be nonspecific constitutional symptoms or organ-specific symptoms. About a third will have a nonspecific presentation with fever, fatigue, cachexia and lassitude and this presentation is more common in people of black or Indian origin.
  • An acute presentation is more common in white patients, as is remission of disease about two years after presentation.
  • About 10-30% of patients will have a chronic, progressive pattern of disease.
  • Black patients have more serious pulmonary involvement with a poorer long-term prognosis and an increased frequency of relapses.

Constitutional upset

  • Fever and night sweats, malaise, fatigue,[4] weight loss.
  • Heerfordt's syndrome (inflammation of submaxillary/parotid glands with uveitis and facial nerve palsy) may accompany constitutional presentation.[5]


  • Involved in >90% cases.
  • The usual pattern is interstitial lung disease (diffuse parenchymal lung disease).
  • Patients may present with dry cough, fever and dyspnoea accompanied by chest discomfort.


  • This is commonly affected. Sarcoidosis may cause a diverse variety of skin manifestations and may resemble both common and rare cutaneous diseases.[6] 
  • Papules may be seen on the face and resembling rosacea or maculopapular rashes on the body or extremities. Brownish-red infiltrative plaques on the extremities and trunk may be present (very similar in appearance to plaque psoriasis).
  • Erythema nodosum on the legs is a relatively common feature. Löfgren's syndrome refers to the combination of erythema nodosum with arthritis (commonly affecting the ankles) and bilateral hilar or paratracheal adenopathy seen on CXR.
  • Lupus pernio is a violaceous, soft infiltration affecting the nose and cheeks that is uncommon but pathognomonic.

The eye

  • This is affected in >20% of cases, most frequently as a granulomatous uveitis.
  • Anterior uveitis is frequently of limited duration, but posterior uveitis tends to be more persistent.
  • Dry eyes and glaucoma can appear years after other symptoms have disappeared.
  • The optic nerve may be affected but severe sight impairment (blindness) is rare.


  • Infiltrative nerve lesions can affect any part of the central or peripheral nervous system, leading to a huge variety of neurological disease.
  • Bell's palsy and lymphocytic meningitis are common manifestations of neurological involvement but diabetes insipidus is also seen.
  • The following symptoms are encountered relatively commonly as a result of neurological involvement:

Heart disease

This can (rarely) cause sudden death from arrhythmias or cause symptoms of heart failure in a young patient, due to cardiomyopathy.[7] 


This is commonly picked up on CXR but may be symptomatic and affect the axillary, cervical, and inguinal nodes and those around the salivary glands.


There may be deranged LFTs but symptoms are rare, causing significant hepatitis in <10% cases.

Hypercalcaemia and hypercalciuria

  • Caused by humoral effect of granulomata on vitamin D3 metabolism.
  • Can cause nephrolithiasis, neuropsychiatric disturbance, abdominal pain and bone pain.


It tends to present as an inflammatory arthritis (often oligoarticular initially) with periarticular soft-tissue swelling, tenosynovitis, dactylitis, osteopenia and associated myopathy.[8]

Other organs/systems

Other areas that are more rarely involved and the symptoms they cause are listed here:

  • Bone marrow (leading to anaemia, immunosuppression).
  • Spleen (causing abdominal discomfort and distension due to splenomegaly).
  • Upper respiratory tract (causing nosebleeds, rhinitis, nasal obstruction/masses or tonsillar involvement).
  • Salivary glands (causing facial swelling and pain and other symptoms of parotitis).

In a patient who is suspected of suffering from sarcoidosis, the following examination scheme will give a good chance of detecting any relevant signs that may suggest or confirm the diagnosis:


Carefully examine the skin all over, looking for characteristic rashes. Lupus pernio (chronic raised hardened, often purple lesion) may be seen on the face, and the shins should be looked at to detect erythema nodosum. Old scars or tattoos may show granulomatous infiltrative lesions.


Look carefully at the eyes to detect signs of uveitis, dry eyes or conjunctival infiltrates. Consider slit-lamp examination if any abnormalities are found (this usually needs expert input).

Joints and muscles

Examine any painful joints and muscles and characterise the nature of the problem and affected structures.

Head and neck

Check for lymphadenopathy, salivary gland swelling, tonsillar enlargement/inflammation and patency/abnormality of nasal passages if there are any relevant symptoms.


Check for hepatomegaly and splenomegaly.


Chest signs of sarcoidosis are usually not detected unless advanced interstitial lung disease is present, when there may be scattered crackles. Check the pulse to detect any rhythm disturbance. Look for signs of heart failure.

Nerves/central nervous system (CNS)

Check the function of the VIIth and other cranial nerves and peripheral sensory/motor nerve function to detect peripheral neuropathy. Formal neurological examination is appropriate if there are relevant symptoms.

The differential diagnosis is huge depending on the type of presentation, affected organs, age of the patient and ethnic origin/recent travel history. The diagnoses listed below have frequent, overlapping clinical and investigational features with sarcoidosis and are important to consider or exclude where relevant:

  • Blood tests:
    • FBC may show raised white count/eosinophilia or lymphopenia. Anaemia may be seen.
    • ESR is often raised (~ 65% of cases).
    • Check U&E, creatinine (renal impairment is quite rare) and serum calcium (elevated in 10-15% of cases). Phosphate and alkaline phosphatase may be increased. LFTs may show derangement.
    • If calcium is elevated then 24-hour urinary collection can prove hypercalciuria.
    • Serum angiotensin-converting enzyme (ACE):
      • Levels are elevated in around 60% of patients with acute disease and reduce in response to treatment or resolution of the disease.
      • The serum ACE level has only a limited role in diagnosis and does not contribute to monitoring patients with pulmonary sarcoidosis when added to serial lung function and imaging.[9] 
    • The tuberculin skin test (Mantoux) is classically negative in patients with sarcoidosis. A positive test result raises the possibility of tuberculosis.[2] 
  • Plain CXR may show bilateral hilar or paratracheal lymphadenopathy. High-resolution CT scanning is often used to detect interstitial lung disease.
  • Lung function tests show restrictive defect in severe, progressive cases (shrinking lung syndrome).
  • ECG is important to check for early signs of rhythm disturbance due to conducting system disease or effects of hypercalcaemia. 24-hour ECG may be used to detect paroxysmal rhythm disturbance.
  • Pulmonary sarcoidosis:
    • Bronchoalveolar lavage findings: increased lymphocytes, especially raised CD4:CD8 ratio, can help to clinch diagnosis in the correct circumstances.
    • Transbronchial biopsy can demonstrate the presence of non-caseating granulomata, giving a more accurate diagnosis.
    • For patients with suspected stage I or II (see 'Staging', below) pulmonary sarcoidosis undergoing tissue confirmation, the use of endosonographic nodal aspiration has been shown to provide greater diagnostic yield compared with bronchoscopic biopsy.[10] 
  • Fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) can be used to assess inflammatory activity accurately in patients with unexplained, persistent, disabling symptoms without serological inflammatory activity, and can help to predict pulmonary deterioration at one year, and the pulmonary improvement expected after treatment.[1] 
  • Gallium scanning may be used to detect extrapulmonary disease and tends to reveal a 'lambda' pattern.
  • Diagnosis may be achieved by biopsy of any suspicious skin lesions or accessible lymph nodes. There will be multiple non-caseating epithelioid granulomata.
  • Formal ophthalmological examination is recommended for all newly diagnosed cases.

Kveim's test (intradermal injection of splenic material from a confirmed case of sarcoidosis, and histological examination of any nodule formed) has fallen out of favour due to the risk of transmission of new-variant Creutzfeldt-Jakob disease (nvCJD), and the several weeks it takes to get a diagnosis.

Traditionally, pulmonary involvement has been classified into five stages based on CXR findings. The prognostic value of this classification in children is uncertain. Note that CXR may also demonstrate pleural involvement, such as a pneumothorax or pleural effusion.

  • Stage 0 - normal findings on chest radiograph.
  • Stage I - bilateral hilar lymphadenopathy (which may be accompanied by paratracheal adenopathy).
  • Stage II - bilateral hilar adenopathy with pulmonary infiltrates (parenchymal involvement or reticular opacities).
  • Stage III - parenchymal infiltrates without hilar adenopathy.
  • Stage IV - parenchymal involvement turns into volume loss (pulmonary fibrosis) and there may be other features (cavitations, calcifications, hilar retraction, bullae, cysts, and emphysema).

Pulmonary disease

Treatment is mainly symptomatic and the mainstay remains the use of oral corticosteroids.[11] 

  • Patients with early disease (hilar lymphadenopathy only) often do not require any therapy.
  • Systematic reviews have demonstrated evidence of benefit from use of steroids in the short term, in terms of symptoms and X-ray appearances, but there is no real convincing proof of benefit in the long term.[12]
  • Consensus guidelines state that steroids should be continued for 12 months but not beyond two years in those who respond, with the dose tapered down as low as possible and given on alternate days if feasible.
  • Consideration of prophylaxis against osteoporosis with bisphosphonate drugs is recommended but calcium and vitamin D are usually avoided due to the risk of hypercalcaemia in sarcoidosis.
  • Given the significant morbidity attributable to long-term use of steroids, they should be given with extreme caution and under expert monitoring in patients with pulmonary sarcoidosis.
  • There is no current evidence of any efficacy for inhaled corticosteroids.

As of yet, systematic reviews have not revealed that immunosuppressant drugs have benefits that outweigh their significant toxic effects in this scenario.[13] Examples of these medications include:[11] 

  • Methotrexate.
  • Antimalarials (eg, chloroquine and hydroxychloroquine).
  • Azathioprine.
  • Leflunomide (analogue to methotrexate with less toxicity).
  • Mycophenolate mofetil (reversible inhibitor of inosine monophosphate dehydrogenase in purine biosynthesis).
  • Cyclophosphamide (alkylating agent with immunosuppressive and anti-inflammatory effects).
  • Tumour necrosis factor (TNF) alpha antagonists (eg, infliximab, adalimumab).

Surgical intervention may be considered in extreme cases of fibrotic lung disease with life-threatening haemoptysis. Lung transplantation has also (rarely) been used.

Extrapulmonary disease[11] 

Corticosteroids are also the initial drug of choice to treat most forms of extrapulmonary sarcoidosis.

Eye sarcoidosis

  • May cause an isolated anterior uveitis confined to the anterior chamber. Topical corticosteroids (eye drops) can then be used without oral corticosteroids.
  • If there is an associated intermediate and/or posterior uveitis then oral corticosteroids will be required.
  • Intraocular corticosteroid injections may be given when eye sarcoidosis extends deeper than the anterior chamber.
  • A shorter course (eg, 3–6 months) of corticosteroids for sarcoid uveitis is usually recommended because both sarcoidosis and corticosteroid therapy can lead to cataracts and glaucoma. Corticosteroid-sparing agents are therefore considered earlier than with other forms of sarcoidosis.
  • Sarcoidosis may cause an acute optic neuritis which is vision-threatening. High-dose intravenous corticosteroids should be strongly considered.

Neurosarcoidosis is relatively refractory to corticosteroids. It has therefore been recommended by some authorities that the initial corticosteroid dose for neurosarcoidosis should be 40-80 mg of daily prednisolone equivalent.


  • Cutaneous sarcoidosis almost never causes significant medical problems and is, therefore, treated only if it is of cosmetic importance to the patient. The initial corticosteroid dose is 20–40 mg of daily prednisolone equivalent.
  • For one or a few small lesions, intralesional injections of triamcinolone acetonide are often effective. Topical corticosteroid creams may also be used but are probably not as effective as intralesional injections.
  • Lupus pernio is disfiguring. Although lupus pernio lesions usually improve with corticosteroid therapy, these lesions usually require infliximab therapy for significant resolution.


Non-steroidal anti-inflammatory agents should be used prior to consideration of corticosteroid or other immunosuppressive therapy.

Complications occur according to the organ affected, but are subject to variability in incidence and severity.

  • Pulmonary:
    • Infections.
    • Pulmonary embolism.[1] 
    • Progressive fibrotic lung disease leading to death.
    • Pulmonary hypertension.[14]
  • Cardiac:
    • Cardiac arrhythmia and sudden death.
    • Cardiac failure.
  • Ocular:
    • Uveitis and conjunctivitis.
    • Severe sight impairment (rare).
    • Ocular sicca syndrome.
  • Skin:
    • Chronic refractory skin disease.
  • Liver:
    • Commonly involved but rarely clinically significant.
  • Nervous system:
    • Cranial and peripheral nerve damage.
    • Neuropsychiatric illness.
    • Permanent CNS impairment.
    • Stroke/TIA.
  • Ear, nose and throat:
    • Salivary gland dysfunction.
    • Nosebleeds, nasal obstruction.
  • Others:
    • Lymphatic (evidence of hypersplenism).
    • Sarcoidosis can be associated with increased incidence of lymphoma.[1] 
    • Hypercalcaemia.
    • Nephrolithiasis.
    • Arthritis and joint damage.

About 20% of patients have permanent clinical symptoms because of irreversible fibrosis, mainly pulmonary fibrosis.

Patients with sarcoidosis have a lower survival rate than that of the general population. Premature death is most often due to advanced pulmonary fibrosis and less often due to cardiac, CNS and hepatic involvement.

Most patients with advanced lung disease die from respiratory failure, pulmonary hypertension or both. Other causes of death include haemoptysis from aspergilloma.

Although sarcoidosis cannot be prevented, some preventative measures may reduce complications. For example:

  • Influenza vaccination.
  • Osteoporosis prophylaxis (steroid usage).
  • Patient education (early treatment of extrapulmonary complications such as uveitis and arrhythmias).
  • Smoking cessation advice (although evidence is lacking to show it causes deterioration in pulmonary sarcoidosis).

Further reading & references

  1. Valeyre D, Prasse A, Nunes H, et al; Sarcoidosis. Lancet. 2013 Sep 30. pii: S0140-6736(13)60680-7. doi: 10.1016/S0140-6736(13)60680-7.
  2. Dempsey OJ, Paterson EW, Kerr KM, et al; Sarcoidosis. BMJ. 2009 Aug 28;339:b3206. doi: 10.1136/bmj.b3206.
  3. Wu J and Rashcovsky Schiff K Sarcoidosis; Am Fam Phys 2004 July 15; 70(2):312-331; [Full Text]
  4. Lower EE, Harman S, Baughman RP; Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of Sarcoidosis Associated Fatigue. Chest. 2008 Feb 8;.
  5. Blair MP, Rizen M; Heerfordt syndrome with internal ophthalmoplegia. Arch Ophthalmol. 2005 Jul;123(7):1017.
  6. Haimovic A, Sanchez M, Judson MA, et al; Sarcoidosis: a comprehensive review and update for the dermatologist: part I. Cutaneous disease. J Am Acad Dermatol. 2012 May;66(5):699.e1-18; quiz 717-8. doi: 10.1016/j.jaad.2011.11.965.
  7. Seward JB, Casaclang-Verzosa G; Infiltrative cardiovascular diseases: cardiomyopathies that look alike. J Am Coll Cardiol. 2010 Apr 27;55(17):1769-79. doi: 10.1016/j.jacc.2009.12.040.
  8. Torralba KD, Quismorio FP Jr; Sarcoid arthritis: a review of clinical features, pathology and therapy. Sarcoidosis Vasc Diffuse Lung Dis. 2003 Jun;20(2):95-103.
  9. Interstitial lung disease guideline; British Thoracic Society (September 2008)
  10. Bauner KU, Wintersperger B; [MRI in cardiac sarcoidosis and amyloidosis]. Radiologe. 2013 Jan;53(1):54-60. doi: 10.1007/s00117-012-2386-0.
  11. Beegle SH, Barba K, Gobunsuy R, et al; Current and emerging pharmacological treatments for sarcoidosis: a review. Drug Des Devel Ther. 2013 Apr 12;7:325-38. doi: 10.2147/DDDT.S31064. Print 2013.
  12. Paramothayan NS, Lasserson TJ, Jones PW; Corticosteroids for pulmonary sarcoidosis. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD001114.
  13. Paramothayan S, Lasserson TJ, Walters EH; Immunosuppressive and cytotoxic therapy for pulmonary sarcoidosis. Cochrane Database Syst Rev. 2006 Jul 19;3:CD003536.
  14. Baughman RP, Engel PJ, Meyer CA, et al; Pulmonary hypertension in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2006 Jun;23(2):108-16.

Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. EMIS has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.

Original Author:
Dr Richard Draper
Current Version:
Peer Reviewer:
Prof Cathy Jackson
Document ID:
2748 (v23)
Last Checked:
Next Review:

Did you find this health information useful?

Yes No

Thank you for your feedback!

Subcribe to the Patient newsletter for healthcare and news updates.

We would love to hear your feedback!

Patient Access app - find out more Patient facebook page - Like our page